Summain, The efficacv and modes of action of dibromodulcitol (DBD) and cisplatin (CDDP) were studied in several model systems. Combination treatments produced a longer survival time in mice bearing P388 solid lymphomas than either of the drugs alone. In the human metastatic melanoma HT-168 xenograft model the combined application of DBD and CDDP was also very effective, inducing a reduction in the number and volume of metastatic nodules. For V79 spheroids. DBD was mainly cytotoxic against the internal, quiescent cells, whereas cisplatin primarily killed cells in the proliferating, external regions of the spheroids. When combined, the drugs appeared to act synergistically throughout the spheroids. Studies on plasmid DNA showed that CDDP primarily generates cross-links, whereas single-strand breaks were dominant after DBD treatment. Upon using an assay for cleavage by restriction nuclease, antagonistic action of DBD and CDDP in combination may occur, nevertheless more strand breaks were always observed in these samples. These results suggest that the efficacy of combined DBD and CDDP is in part a result of 'spatial cooperation' by the drugs (i e. affecting different cells) and in part the result of DNA damage produced by the combination treatments.
Dibromodulcitol (DBD) has been shown to induce alterations in chromatin components. including binding to DNA (Jeney et al.. 1979; Institons and Tamas. 1983) . It is effective against various experimental and human tumours. such as cervical carcinoma and melanoma, in which cis-diamminedichloroplatinum II (CDDP) is also a treatment of choice (Bellet et al.. 1978 : Stehman et al.. 1989 . As DBD and CDDP have different organ toxicities. clinical trial of these two drugs in combination therapy is already under consideration. The aim of the present study was to evaluate the efficacy of CDDP + DBD treatment both in vivo and in vitro. The combined action of these two drugs was investigated in mice bearing P388 solid lymphomas and in a metastatic human melanoma xenograft model transplanted either subcutaneously or intrasplenically.
Since oxygen and nutrient supplies are often limited in malignant tumours and can influence the therapeutic response, including in cervical carcinoma and melanoma, both of which are sensitive to DBD, the differential cytotoxic potential of DBD and CDDP against normoxic and hypoxic tumour cells was investigated. In Chinese hamster V79 multicell spheroids, CDDP exhibited less activity against cells in the nutrient-deprived and hypoxic regions of the spheroids than in the external cells (Durand, 1986) . Since preliminary experiments showed that DBD had essentially the opposite activity, it was naturally of interest to evaluate DBD in combination with cisplatin at various depths within the spheroids using cell sorting techniques (Durand, 1982) .
To test the possibility that DBD or one of its solvolytic products, i.e. 1,2:5,6-dianhydro-dulcitol (DAD) or 1-bromo-1-deoxy-3-6-anhydro-DL dulcitol (BAD), preferentially attacked other base sequences than CDDP, changes of cleavage of plasmid DNA by restriction nucleases were studied. In addition, the DNA interstrand cross-linking ability of DBD and CDDP was also determined. (Durand, 1982 (Durand, . 1986 ). After the analysis of the effects of the two agent treatments. the observed and the expected survival curves were plotted as described previously (Durand. 1990 after the administration of 750 mg kg-' DBD and 7 mgkg-' CDDP. Figure 2 shows that tumour volumes for subcutaneous xenografts of HT168 human melanoma after the combined treatment with CDDP and DBD were significantly reduced.
The doubling time changes also indicated the greater antitumour action of this combination relative to CDDP or DBD alone; the value for the untreated tumour was 6.2 days, which was prolonged to 9.0, 13.1 and 20.7 days in the CDDP-DBD-and CDDP + DBD-treated experimental groups respectively.
In another series of experiments, the effects of this combination on metastasis formation from the same tumour transplanted into the spleen were investigated (Table I) . Notably, the number of metastatic nodules was 86% higher after CDDP treatment compared with the control value. Most interestingly, this adverse response to CDDP was abolished if DBD was administered, especially if CDDP was given first and then DBD. Conversely, the total volume of all metastatic nodules per liver was a lower level in all drugtreated groups. This implies that, while the cellular growth rate in the metastatic nodules could be reduced, the actual number of tumour cells seeding the liver was unaffected by single-agent treatment. The observation that the combined application of CDDP followed by DBD reduced both the number and the volume of the metastatic nodules thus appears quite significant.
Unfortunately, the combined action of CDDP + DBD caused a significant reduction in body-weight (Figure 3 ). To avoid host toxicity the mice were hydrated 30 min before and 30 min after CDDP treatment by administering 0.5 ml of 0.9% sodium chloride. Figure 3 shows that no extreme loss of body weight was observed in the hydrated mice after CDDP + DBD treatment, indicating that toxic action of the combination could be reduced.
As in previous reports, the external cycling cells of the V79 spheroids were most sensitive to CDDP, with less cytotoxicity at greater depths within the spheroids (Figure 4 ). These studies provide the first indication that DBD action is qualitatively different from that of CDDP, as can be clearly seen from the differing sensitivity proffles in Figure 4 . Interestingly, DBD decreased the clonogenic capacity of the internal cells more extensively than those cells of the external region. suggesting a potential role of hypoxia in modulating DBD activity. The combined application of DBD and CDDP resulted in more cytotoxicity; the response was apparently more than additive (Figure 4a and b (Table  II) . Measurements of cross-link formation led to the conclusion that CDDP and DBD treatment induce different types of DNA damage. as it was shown that CDDP induces crosslinkage, whereas after DBD treatment formation of single strand breaks was the dominant change ( Figure 5 ). factors might contribute to the enhanced anti-tumour efficacy upon the combined application of these agents. Since cellassociated drug metabolism is not a prerequisite step for either CDDP or DBD action there seemed to be no objection to using naked DNA to investigate the combined action of these drugs. The biological changes induced by the combined application of DBD + CDDP showed certain qualitative differences from the action of either drug alone. This was apparent in the human metastatic model (HT-168 melanoma) in which DBD was not effective and CDDP increased the number and decreased the volume of the metastatic nodules (Table II) . It is noteworthy that the combined use of the two drugs resulted in a significant reduction in both the number and volume of the metastatic nodules. This raised the question of whether greater anti-tumour efficacy of this combination could develop at a cell population or at a molecular level. Investigation using the V79 spheroids led to the conclusion that cells located at the external and internal regions of the spheroids show different sensitivity to DBD and CDDP. Studies on plasmid DNA showed that DBD treatment causes primarily single-strand breaks. whereas cross-links are formed after CDDP treatment. The two drugs acted synergistically in the production of strand breaks. but the number of CDDP-induced cross-links was reduced in the presence of DBD. Drug antagonism in this model system may be due to the solvolytic metabolites of DBD. because the mecham'sm of action of DAD and BAD in reversing the effect of CDDP was different in the BamHI and Sma nuclease assays, and in the latter assay system DBD showed no interference in CDDP action. These findings may be an explanation for the dose-dependent synergism between DBD and CDDP if one considers the possibility that the ratio of the metabolites generated from DBD is dose dependent (Figure 1 ). The formation of BAD and DAD from DBD was characterised as solvolysis and both compounds were identified both in the plasma of patients treated with DBD and in a cell-free system (Horvath et al., 1979 (Horvath et al., . 1982 Vidra et al.. 1982; Kelley et al., 1986) . It is conceivable that DBD + CDDP synergism may be determined by the type and concentration of DBD metabolites.
In the last few years, more emphasis has been placed on drug activity in hypoxic tumour cells, and several methods of killing hypoxic tumour cells are currently being investigated (Sartorelli. 1988) . Numerous new chemical entities have been designed which have no reactive capacity unless they are activated by bioreductive processes under hypoxic conditions (Sartorelli, 1988; Walton et al., 1989) . Often, the cytotoxic action of such agents can be augmented through manipulation of blood flow (Brown. 1991 (Olive and Durand. 1994) . Consequently. factors other than hypoxia could determine the higher efficacy of DBD against the cells located at the internal region of the spheroid.
In addition to the complementary toxicity patterns for DBD and CDDP. our data also suggest synergistic interactions at the tumour, cellular and DNA levels. The marked increase in DNA strand break production by combination treatments is notable, as is the apparent 'antagonism' of the drugs in some cleavage assays. The latter results presumably indicate a qualitative difference in the molecular lesions formed, a result not incompatible with synergistic cytotoxicity. These observations clearly require additional study.
In summary, dibromodulcitol appears to be a promising new chemotherapeutic agent owing to its preferential toxicity towards hypoxic cells in vitro. This utility is amplified by the observed synergism with cisplatin. and suggests that DBD may also prove efficacious in combination with a number of other conventional cancer chemotherapy agents.
